BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-padcev-keytruda-mibc-pdufa-aug172026@catalyst-calendar.local
DTSTAMP:20260720T200526Z
DTSTART:20260818T035900Z
DTEND:20260818T042900Z
SUMMARY:Padcev+Keytruda肌层浸润性膀胱癌扩展适应症PDUFA窗口
DESCRIPTION:Pfizer/Astellas与Merck的Padcev加Keytruda或Keytruda QLEX用于围手术期治疗肌层浸润性膀胱癌、无论顺铂适用性的sBLA获FDA优先审评，PDUFA目标日期为2026年8月17日。\\nImpact score: 72\\nExpected: 决定将影响尿路上皮癌围手术期治疗标准、ADC+PD-1组合商业空间及Keytruda生命周期管理。\\nAffected: PFE(subject\, unknown\, score 66)\; MRK(subject\, unknown\, score 70)\; 4503.T(subject\, unknown\, score 68)\; IBB(etf\, mixed\, score 48)\; 09926.HK(peer\, mixed\, score 54)\\nSources: Pfizer PADCEV Keytruda Priority Review: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-grants-priority-review-sbla-padcevtm-keytrudar\\nMerck Keytruda PADCEV Priority Review: https://www.merck.com/news/fda-grants-priority-review-for-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-with-padcev-enfortumab-vedotin-ejfv-for-cisplati/\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-padcev-keytruda-mibc-pdufa-aug172026
CATEGORIES:fda\,US\,FDA\,PDUFA\,bladder cancer\,ADC\,PD-1
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Padcev+Keytruda肌层浸润性膀胱癌扩展适应症PDUFA窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Padcev+Keytruda肌层浸润性膀胱癌扩展适应症PDUFA窗口
END:VALARM
END:VEVENT
END:VCALENDAR